Finerenone (BAY94-8862): intervention A + Finerenone (BAY94-8862): intervention B
Phase 1CompletedDevelopment Stage
Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent
Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers
May 2, 2023 → Jul 28, 2023
About Finerenone (BAY94-8862): intervention A + Finerenone (BAY94-8862): intervention B
Finerenone (BAY94-8862): intervention A + Finerenone (BAY94-8862): intervention B is a phase 1 stage product being developed by Bayer for Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent. The current trial status is completed. This product is registered under clinical trial identifier NCT07116512. Target conditions include Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07116512 | Phase 1 | Completed |
Competing Products
20 competing products in Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| IV Loop Diuretics | Nuwellis | Pre-clinical | 15 |
| Stepped pharmacologic care | Nuwellis | Phase 3 | 69 |
| IV Loop Diuretics (LD) | Nuwellis | Pre-clinical | 15 |
| TRV120027 + Normal Saline | Trevena | Phase 1 | 25 |
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| TRV120027 + Placebo | Trevena | Phase 1/2 | 33 |
| Ilofotase alfa + Placebo | AM-Pharma | Phase 2 | 44 |
| INXN-4001 | Precigen | Phase 1 | 28 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| SGLT2i, beta blocker, ARNI, MRA, MTD | Eli Lilly | Approved | 85 |
| Pactimibe, CS-505 | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 85 |
| olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil | Daiichi Sankyo | Phase 3 | 77 |
| Olmesartan | Daiichi Sankyo | Phase 3 | 77 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| Advagraf + Prograf | Astellas Pharma | Phase 2 | 52 |
| FK506E | Astellas Pharma | Phase 3 | 77 |